AnaptysBio
Transforming patient health by delivering innovative immunology therapeutics.
144 employees · est. 2005 · San Diego, United States
Neuron23
Combining cutting-edge science, human genetics, and a patient-centered approach to transform how we treat Parkinson’s.
28 employees · est. 2018 · South San Francisco, United...
AnaptysBio is the older company (2005 vs 2018); AnaptysBio is the larger of the two.
Side-by-Side Comparison
| Metric | AnaptysBio | Neuron23 |
|---|---|---|
| Founded | ||
| Founded | 2005 older | 2018 |
| Headquarters | ||
| Headquarters | San Diego, United States | South San Francisco, United States |
| Employees | ||
| Employees | 144 larger | 28 |
| Industry | ||
| Industry | Biotechnology, Health Care, Health and Wellness | Not tracked yet |
| Funding Stage | ||
| Funding Stage | IPO | Series D |
| Total Funding | ||
| Total Funding | $185.90M | $230.00M |
| Funding Rounds | ||
| Funding Rounds | 7 | 4 |
| Services | ||
| Services | Development of innovative immunology therapeutics, Clinical trials for autoimmune and inflammatory diseases, Research and development of best-in-class antibodies | Development of precision medicine for Parkinson's Disease, Clinical trials for novel therapeutic approaches, Research and development in neuroimmunology and neuroscience |
| Target Customers | ||
| Target Customers | Patients with autoimmune and inflammatory diseases, Healthcare providers in the field of immunology, Investors interested in biotechnology and pharmaceuticals | Patients with Parkinson's Disease, Healthcare providers specializing in neurology, Pharmaceutical and biotechnology investors |
| Taxonomy | ||
| Taxonomy | Immunology Therapeutics, Clinical-stage Biotechnology, Immune Cell Modulators, Checkpoint Agonists, Autoimmune Diseases, Inflammatory Diseases, Antibodies, Cancer Immunotherapy, Inflammation, Biotechnology Company | Precision Medicine, Parkinson's Disease, Neurodegenerative Diseases, Human Genetics, Biomarker Platform, Drug Discovery, Neurological Diseases, Alzheimer's Disease, Clinical-stage Biotechnology, Hyperactive LRRK2, Patient-centered Approach, Neuroinflammatory Diseases, Autoimmune Diseases |
| Website | ||
| Website | anaptysbio.com | neuron23.com |
About AnaptysBio
AnaptysBio is a clinical-stage biotechnology company that has been crafting its legacy since its founding in 2005. Specializing in the discovery and development of innovative immunology therapeutics, the company's mission is succinctly captured in its slogan: "Transforming patient health by deliveri...
About Neuron23
Neuron23, founded in 2018, is a clinical-stage biotechnology company based in the United States. The company is pioneering advancements in precision medicine, specifically targeting Parkinson’s disease driven by hyperactive LRRK2. By integrating cutting-edge science with human genetics and its propr...
We will tell you when either one moves
BounceWatch watches AnaptysBio and Neuron23 for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.
Funding, hiring, leadership and stack changes at AnaptysBio and Neuron23 — by email.
Frequently Asked Questions
Compare AnaptysBio with someone else
Start typing a company name or domain.
Related Comparisons
Compiled from the BounceWatch company index. We last looked at AnaptysBio on 12 Sep 2024, and Neuron23 on 31 Mar 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.